BACKGROUND: There is little information on multiple human papillomavirus (HPV) infections and the potential for type competition in men, yet competition may impact the type-specific efficacy of HPV vaccination. METHODS: Among 2702 uncircumcised men in Kisumu, Kenya, who were seronegative for human immunodeficiency virus, the observed numbers of HPV types detected were compared with the expected number, which was simulated under the assumption of independent infections. To assess the potential for HPV type competition, adjusted odds ratios for pairwise combinations of prevalent HPV type infections were estimated using semi-Bayesian methods. RESULTS: Half of all men were HPV positive, of whom 57% had multiple HPV types. We observed men without HPV infection and with ≥4 HPV types more often than expected if infections were independent. No negative associations between individual HPV types were observed. HPV types 31, 39, 56, 58, and 59 were positively associated with both carcinogenic vaccine types HPV-16 and HPV-18 (2-sided P value <.05). CONCLUSIONS: Men who were HPV infected were likely to test positive for >1 HPV type. Cross-sectional associations between individual HPV types were positive and did not appear to be type-specific. Thus, we did not identify HPV types that are candidates for potential HPV type competition in men.
BACKGROUND: There is little information on multiple human papillomavirus (HPV) infections and the potential for type competition in men, yet competition may impact the type-specific efficacy of HPV vaccination. METHODS: Among 2702 uncircumcised men in Kisumu, Kenya, who were seronegative for human immunodeficiency virus, the observed numbers of HPV types detected were compared with the expected number, which was simulated under the assumption of independent infections. To assess the potential for HPV type competition, adjusted odds ratios for pairwise combinations of prevalent HPV type infections were estimated using semi-Bayesian methods. RESULTS: Half of all men were HPV positive, of whom 57% had multiple HPV types. We observed men without HPV infection and with ≥4 HPV types more often than expected if infections were independent. No negative associations between individual HPV types were observed. HPV types 31, 39, 56, 58, and 59 were positively associated with both carcinogenic vaccine types HPV-16 and HPV-18 (2-sided P value <.05). CONCLUSIONS:Men who were HPV infected were likely to test positive for >1 HPV type. Cross-sectional associations between individual HPV types were positive and did not appear to be type-specific. Thus, we did not identify HPV types that are candidates for potential HPV type competition in men.
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: Helen Trottier; Salaheddin Mahmud; Maria Cecilia Costa; João P Sobrinho; Eliane Duarte-Franco; Thomas E Rohan; Alex Ferenczy; Luisa L Villa; Eduardo L Franco Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-07 Impact factor: 4.254
Authors: Anil K Chaturvedi; Leann Myers; Ansley F Hammons; Rebecca A Clark; Kathleen Dunlap; Patricia J Kissinger; Michael E Hagensee Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-10 Impact factor: 4.254
Authors: Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr Journal: Lancet Oncol Date: 2005-05 Impact factor: 41.316
Authors: Susanne Krüger Kjaer; Christian Munk; Jeanette Falck Winther; Hans Ole Jørgensen; Chris J L M Meijer; Adriaan J C van den Brule Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin Journal: Lancet Date: 2004 Nov 13-19 Impact factor: 79.321
Authors: Jason Bailey Reed; Emmanuel Njeuhmeli; Anne Goldzier Thomas; Melanie C Bacon; Robert Bailey; Peter Cherutich; Kelly Curran; Kim Dickson; Tim Farley; Catherine Hankins; Karin Hatzold; Jessica Justman; Zebedee Mwandi; Luke Nkinsi; Renee Ridzon; Caroline Ryan; Naomi Bock Journal: J Acquir Immune Defic Syndr Date: 2012-08-15 Impact factor: 3.731
Authors: Anne F Rositch; Michael G Hudgens; Danielle M Backes; Stephen Moses; Kawango Agot; Edith Nyagaya; Peter J F Snijders; Chris J L M Meijer; Robert C Bailey; Jennifer S Smith Journal: J Infect Dis Date: 2012-06-18 Impact factor: 5.226
Authors: Maarten F Schim van der Loeff; Sofie H Mooij; Oliver Richel; Henry J C de Vries; Jan M Prins Journal: Curr HIV/AIDS Rep Date: 2014-09 Impact factor: 5.071
Authors: Markus Schmitt; Christophe Depuydt; Ina Benoy; Johannes Bogers; Jerome Antoine; Marc Arbyn; Michael Pawlita Journal: J Clin Microbiol Date: 2013-02-27 Impact factor: 5.948
Authors: Joseph E Tota; Agnihotram V Ramanakumar; Luisa L Villa; Harriet Richardson; Ann N Burchell; François Coutlée; Eduardo L Franco Journal: J Infect Dis Date: 2016-06-02 Impact factor: 5.226
Authors: Joseph E Tota; Agnihotram V Ramanakumar; Mengzhu Jiang; Joakim Dillner; Stephen D Walter; Jay S Kaufman; François Coutlée; Luisa L Villa; Eduardo L Franco Journal: Am J Epidemiol Date: 2013-05-09 Impact factor: 4.897
Authors: Frédéric M Hamelin; Linda J S Allen; Vrushali A Bokil; Louis J Gross; Frank M Hilker; Michael J Jeger; Carrie A Manore; Alison G Power; Megan A Rúa; Nik J Cunniffe Journal: PLoS Biol Date: 2019-12-03 Impact factor: 8.029